Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Ty O'Neil/SOPA Images/LightRocket via Getty Images

Sanofi announced Monday it will manufacture up to 200 million doses of Moderna's COVID-19 vaccine at its site in Ridgefield, New Jersey, from September.

Why it matters: The agreement between Sanofi and Moderna should not only boost the U.S. coronavirus vaccine rollout, it should also help global efforts as the doses will likely be exported.

Of note: French multinational pharmaceutical giant Sanofi is the only manufacturer that is producing doses of the Pfizer-BioNTech, Johnson & Johnson and now Moderna, in addition to developing two of its own coronavirus vaccines.

The big picture: More than 1 billion COVID-19 doses have now been produced. The U.S. has administered the most — 23% of the worldwide total, statistics from Our World in Data show.

  • The World Health Organization earlier this month criticized a "shocking imbalance" in vaccine distribution, with poorer nations being left behind.
  • While the U.S. has kept nearly all of its supply for domestic use, it's expected to become a major exporter once its domestic needs are met.

Go deeper: All U.S. adults now eligible for COVID-19 vaccine

Go deeper

Tina Reed, author of Vitals
Apr 26, 2021 - Health

Vaccine hesitancy remains high among essential workers

Eugenio Brito, Vice President of Bodegas of America receives a Pfizer vaccination shot at an event to announce five new walk-in pop-up vaccination sites for New York City Bodega, grocery store and supermarket workers amid the coronavirus disease (COVID-19) pandemic. Photo: by Mike Segar-Pool/Getty Images

Essential workers who are not in health care are less likely to want a vaccine than the rest of the general public, according to new figures from the Kaiser Family Foundation.

Why it matters: As vaccines become more available, health officials are increasingly grappling with vaccine hesitancy, particularly among those most at risk.

Biden's 100-day numbers: Vaccinated Americans

Data: CDC via Our World in Data; Chart: Will Chase/Axios

Joe Biden promised as president-elect to get 100 million coronavirus vaccine shots in American arms during his first 100 days in office; since taking office, he's more than doubled that goal — and more than a quarter of Americans are now fully vaccinated.

By the numbers: Not quite 1% were vaccinated when Biden took office, although the Trump administration managed to reach an important milestone of 1 million doses administered in a day.

Apr 26, 2021 - Health

Poll: 73% of unvaccinated Americans say they won't take the J&J shot

An Army nurse holds a vial of the Johnson & Johnson vaccine at the FEMA-supported COVID-19 vaccination site at Valencia State College on April 25. Photo: Paul Hennessy/SOPA Images/LightRocket via Getty Images

About 3 in 4 unvaccinated adult Americans are unwilling to get the Johnson & Johnson coronavirus vaccine, a Washington Post-ABC News poll out Monday indicates.

Why it matters: Less than half of all U.S. adults polled said they thought the J&J shot — which presents fewer logistical challenges than the more temperature-controlled, two-shot Pfizer and Moderna vaccines — is safe.